126 related articles for article (PubMed ID: 38484250)
1. The Impact of an Overactive Bladder Care Pathway on Longitudinal Patient Management.
Selle JM; Hanson KT; Habermann EB; Gebhart JB; Trabuco EC; Occhino JA; Young AD; Linder BJ
Urogynecology (Phila); 2024 Mar; 30(3):330-336. PubMed ID: 38484250
[TBL] [Abstract][Full Text] [Related]
2. A retrospective longitudinal evaluation of new overactive bladder patients in an FPMRS urologist practice: Are patients following up and utilizing third-line therapies?
Du C; Berg WT; Siegal AR; Huang Z; Nguyen A; Cheung A; Mehraban-Far S; Anderson R; Jacob S; Kim J
Neurourol Urodyn; 2021 Jan; 40(1):391-396. PubMed ID: 33197059
[TBL] [Abstract][Full Text] [Related]
3. Understanding the Pursuit of Third-Line Therapies for Overactive Bladder: A Mixed Methods Study.
Gonzalez JD; Martin L; Osmundsen B; Garg B; Gregory WT; Cichowski S
Urogynecology (Phila); 2024 Mar; 30(3):188-196. PubMed ID: 38484231
[TBL] [Abstract][Full Text] [Related]
4. Overactive bladder in an integrated delivery system: a longitudinal cohort study.
Linder JA; Weissman JS; Reyes Nieva H; Lipsitz S; Haring RS; DeAngelis J; Kristy RM; Loughlin KR
BMC Health Serv Res; 2020 May; 20(1):447. PubMed ID: 32434511
[TBL] [Abstract][Full Text] [Related]
5. National Patterns of Filled Prescriptions and Third-Line Treatment Utilization for Privately Insured Women With Overactive Bladder.
Linder BJ; Gebhart JB; Elliott DS; Van Houten HK; Sangaralingham LR; Habermann EB
Female Pelvic Med Reconstr Surg; 2021 Feb; 27(2):e261-e266. PubMed ID: 31157717
[TBL] [Abstract][Full Text] [Related]
6. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
[TBL] [Abstract][Full Text] [Related]
7. Practice Patterns for Women With Overactive Bladder Syndrome: Time Between Medications and Third-Line Treatments.
Kirby AC; Park S; Cook SB; Odem-Davis K; Gore JL; Wolff EM
Female Pelvic Med Reconstr Surg; 2020 Jul; 26(7):431-436. PubMed ID: 32265405
[TBL] [Abstract][Full Text] [Related]
8. Patient Perceptions Impact Progression to Third-Line Therapy for Treatment of Overactive Bladder.
Iyer S; Amegashie C; deMartelly V; Letko J; Glass D; Fetzer L; Botros S; Wroblewski K; Valaitis S
J Urol; 2021 Nov; 206(5):1240-1247. PubMed ID: 34184922
[TBL] [Abstract][Full Text] [Related]
9. Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women.
Geller EJ; Crane AK; Wells EC; Robinson BL; Jannelli ML; Khandelwal CM; Connolly A; Parnell BA; Matthews CA; Dumond JB; Busby-Whitehead J
Clin Drug Investig; 2012 Oct; 32(10):697-705. PubMed ID: 22873491
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, Risk Factors, and Treatment for Overactive Bladder in a Racially Diverse Population.
Mckellar K; Bellin E; Schoenbaum E; Abraham N
Urology; 2019 Apr; 126():70-75. PubMed ID: 30597170
[TBL] [Abstract][Full Text] [Related]
11. An analysis of factors that influence patient preference of third-line therapy for overactive bladder.
Kapur A; Harandi AA; Cohen T; Ruan H; Dabrowski C; Anderson R; Hwang K; Lee E; Weissbart S; Kim J
Neurourol Urodyn; 2022 Nov; 41(8):1906-1913. PubMed ID: 36104866
[TBL] [Abstract][Full Text] [Related]
12. A Patient-Centered Approach to Refractory Overactive Bladder and Barriers to Third-Line Therapy.
Davenport A; Stark S; Quian A; Sheyn D; Mangel J
Obstet Gynecol; 2019 Jul; 134(1):141-148. PubMed ID: 31188332
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder.
Pelletier EM; Vats V; Clemens JQ
Am J Manag Care; 2009 Mar; 15(4 Suppl):S108-14. PubMed ID: 19355799
[TBL] [Abstract][Full Text] [Related]
14. Management of Patients with Overactive Bladder in Brazil: A Retrospective Observational Study Using Data From the Brazilian Public Health System.
Lozano-Ortega G; Ng DB; Szabo SM; Deighton AM; Riveros B; Guttschow A; Gooch KL; Gomes CM
Adv Ther; 2020 May; 37(5):2344-2355. PubMed ID: 32297282
[TBL] [Abstract][Full Text] [Related]
15. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
[TBL] [Abstract][Full Text] [Related]
16. Primary Nonadherence to Overactive Bladder Medications in an Integrated Managed Care Health Care System.
Rashid N; Vassilakis M; Lin KJ; Kristy R; Ng DB
J Manag Care Spec Pharm; 2017 Apr; 23(4):484-493. PubMed ID: 28345439
[TBL] [Abstract][Full Text] [Related]
17. Bladder training for treating overactive bladder in adults.
Funada S; Yoshioka T; Luo Y; Sato A; Akamatsu S; Watanabe N
Cochrane Database Syst Rev; 2023 Oct; 10(10):CD013571. PubMed ID: 37811598
[TBL] [Abstract][Full Text] [Related]
18. Health Resource Utilization and Cost for Patients with Incontinent Overactive Bladder Treated with Anticholinergics.
Yehoshua A; Chancellor M; Vasavada S; Malone DC; Armstrong EP; Joshi M; Campbell K; Pulicharam R
J Manag Care Spec Pharm; 2016 Apr; 22(4):406-13. PubMed ID: 27023694
[TBL] [Abstract][Full Text] [Related]
19. Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States.
Anger JT; Goldman HB; Luo X; Carlsson MO; Chapman D; Zou KH; Russell D; Ntanios F; Esinduy CB; Clemens JQ
Neurourol Urodyn; 2018 Jan; 37(1):213-222. PubMed ID: 28455944
[TBL] [Abstract][Full Text] [Related]
20. Why Patients Fall Through the Cracks: Assessment of Patients' Overactive Bladder Treatment.
Davidson ERW; Miceli L; Propst K
J Womens Health (Larchmt); 2022 Sep; 31(9):1314-1319. PubMed ID: 35363051
[No Abstract] [Full Text] [Related]
[Next] [New Search]
